Mathematical model may lead to safer chemotherapy
Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the ...
Medical research
Sep 12, 2012 |
not rated yet |
0
|
Moxifloxacin monotherapy equivalent to antibiotic combo
(HealthDay)—Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer ...
Cancer
Jan 30, 2013 |
not rated yet |
0
ASCO issues guideline for febrile neutropenia in adults
(HealthDay)—The American Society of Clinical Oncology has issued updated recommendations for both the prevention and management of febrile episodes in neutropenic oncology outpatients; the recommendations ...
Cancer
Jan 15, 2013 |
not rated yet |
0
Optimal dose suggested for dasatinib in ovarian cancer
(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, ...
Cancer
Nov 19, 2012 |
5 / 5 (1) |
0
New drug approved for lack of certain white blood cells
(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.
Medications
Aug 30, 2012 |
not rated yet |
0
Brentuximab vedotin effective in large-cell lymphoma
(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete ...
Cancer
May 24, 2012 |
not rated yet |
0
Chemo combination promising for multiple myeloma
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response ...
Cancer
May 02, 2012 |
not rated yet |
0
New guidelines issued for pediatric fever and neutropenia
(HealthDay)—New evidence-based guidelines have been compiled on the management of fever and and neutropenia (FN) in children with cancer and/or who are undergoing hematopoietic stem-cell transplantation; ...
Cancer
Sep 19, 2012 |
not rated yet |
0
Bevacizumab active in HIV-linked Kaposi's sarcoma
(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of ...
Cancer
Mar 20, 2012 |
not rated yet |
0
Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research ...
Cancer
Jul 07, 2011 |
not rated yet |
0
